Assessing quality of life during chemotherapy for pleural mesothelioma: Feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module

Journal of Clinical Oncology

Volumn 22, Issue 15, 2004, Pages 3172-3180

  Nowak, Anna K ^a   Stockler, Martin R ^a   Byrne, Michael J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANOREXIA; ARTICLE; CANCER SURVIVAL; COUGHING; DYSPNEA; EUROPE; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HUMAN; INSOMNIA; LUNG CANCER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PAIN; PATIENT COMPLIANCE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL STATUS; VALIDATION PROCESS; AGED; BIOASSAY; COMPARATIVE STUDY; FEASIBILITY STUDY; MESOTHELIOMA; MIDDLE AGED; PATHOPHYSIOLOGY; PLEURA TUMOR; PREDICTION AND FORECASTING; REPRODUCIBILITY; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CISPLATIN; DEOXYCYTIDINE; ENDPOINT DETERMINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PATIENT COMPLIANCE; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 4143082823     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.09.147     Document Type: Article

References (23)

1. Sterman DH, Kaiser LR, Albelda SM: Advances in the treatment of malignant pleural mesothelioma. Chest 116:504-520, 1999
2. Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 14:1007-1017, 1996
3. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
4. Cella D, Eton DT, Fairclough DL, et al: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55:285-295, 2002
5. Hollen PJ, Gralla RJ, Kris MG, et al: Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73:2087-2098, 1994
6. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-42, 1994
7. Nowak AK, Byrne MJ, Williamson R, et al: A multicentre phase Il study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87:491-496, 2002
8. Byrne MJ, Davidson JA, Musk AW, et al: Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 17:25-30, 1999
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644, 2003
10. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
11. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
12. Fayers PM, Aaronson NK, Bjordal K, et al: The EORTC QLQ-C30 Scoring Manual (ed 3). Brussels. Belgium, European Organization for Research and Treatment of Cancer, 2001
13. Hjermstad MJ, Fayers PM, Bjordal K, et al: Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: The QLQ=C30 (+ 3). J Clin Oncol 16:1188-1196, 1998
14. Fayers PM, Weeden S, Curran D: QoLS: EORTC QLQ-C30 Reference Values. Brussels, Belgium, European Organization for Research and Treatment of Cancer, 1998
15. Edwards JG, Abrams KR, Leverment JN, et al: Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 55:731-735, 2000
16. Hjermstad MJ, Fayers PM, Bjordal K, et al: Using reference data on quality of life: The importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 34:1381-1389, 1998
17. Byrne MJ, Nowak AK: Modified RECIST criteria for assessment of response in Malignant Pleural Mesothelioma. Ann Oncol 15:257-260, 2004
18. Steele JP, Shamash J, Evans MT, et al: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912-3917, 2000
19. Bottomley A: The cancer patient and quality of life. Oncologist 7:120-125, 2002
20. Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in health status. Med Care 27:5178-89, 1989 (suppl)
21. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
22. King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555-567, 1996
23. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993